

1 **The branched chain aminotransferase IlvE promotes growth, stress resistance and**
2 **pathogenesis of *Listeria monocytogenes***

3 Karla D. Passalacqua^{a*##}, Tianhui Zhou^{a*}, Tracy A. Washington^b, Basel H. Abuaita^a, Abraham
4 L. Sonenshein^b, Mary X.D. O’Riordan^{a#}

5
6 ^aUniversity of Michigan Medical School, Department of Microbiology & Immunology, Ann
7 Arbor, MI

8 ^bTufts University School of Medicine, Department of Molecular Biology & Microbiology,
9 Boston, MA

10
11 Running title: Branched chain fatty acids in *Listeria*

12
13 [#]Address correspondence to: kpassal@umich.edu; oriordan@umich.edu

14
15 *Karla D. Passalacqua and Tianhui Zhou contributed equally to this work. Author order was
16 determined on the basis of seniority.

17

18 **ABSTRACT**

19 The bacterial plasma membrane is a key interface during pathogen-host interactions, and
20 membrane composition enhances resistance against host antimicrobial defenses. Branched chain
21 fatty acids (BCFAs) are the major plasma membrane component in the intracellular Gram-
22 positive pathogen *Listeria monocytogenes* (Lm) and BCFA metabolism is essential for Lm
23 growth and virulence. BCFA synthesis requires branched chain amino acids (BCAAs), and the
24 BCAA Isoleucine (Ile) is a necessary substrate for the predominant membrane anteiso-BCFAs
25 (ai-BCFAs) as well as an environmental signal for virulence regulation in Lm. In this study, we
26 explored how two proteins that metabolize or sense Ile contribute to Lm growth, BCFA
27 metabolism, and virulence. The IlvE aminotransferase incorporates Ile into ai-BCFAs, while
28 CodY is an Ile-sensing regulator that coordinates BCAA synthesis and virulence gene
29 expression. Analysis of deletion mutants lacking IlvE ($\Delta ilvE$) or CodY ($\Delta codY$) revealed a major
30 role for IlvE under nutrient restriction and stress conditions. Cultures of the $\Delta ilvE$ mutant
31 contained proportionally less ai-BCFAs relative to wild type, while of the $\Delta codY$ mutant had a
32 lower proportion of ai-BCFAs in stationary phase, despite containing more cell-associated Ile.
33 Both $\Delta ilvE$ and $\Delta codY$ mutants required exogenous Ile for optimal growth, but the $\Delta ilvE$ mutant
34 had an absolute requirement for Valine and Leucine when Ile was absent. IlvE was also
35 necessary for resistance to membrane stress, cell-to-cell spread, infection of primary
36 macrophages, and virulence in mice. Our findings implicate IlvE as an integral aspect of Lm
37 stress resistance and emphasize the central importance of Ile in Lm growth and virulence.

38

39 INTRODUCTION

40 The bacterial plasma membrane is a key interface of pathogen-host interactions and an
41 important intrinsic barrier to host antimicrobial defenses. Situated just beneath and intimately
42 connected to the bacterial cell wall, the plasma membrane is a crucial structure of the bacterial
43 cell surface; thus, the interface between bacterium and host cell is of particular importance for
44 intracellular pathogens such as *Listeria monocytogenes* (Lm), the causative agent of listeriosis
45 (1-3). During its infectious cycle, Lm enters mammalian cells and traverses through a range of
46 cellular locales, each with distinct nutrient availability, redox state, and host antibacterial
47 mechanisms (4). Here, the bacterial membrane serves as an environmental sensor and a
48 defensive structure central to intracellular survival and replication (5). Therefore, exploring Lm
49 membrane dynamics is central for elucidating virulence strategies of this important pathogen.

50 As in many Gram-positive bacteria, including *Staphylococcus aureus*, the Lm plasma
51 membrane is predominantly composed of branched chain fatty acids (BCFAs), a structural
52 feature important for bacterial integrity against multiple stresses and during pathogenesis (6-14).
53 Odd numbered (C15, C17) anteiso-BCFAs (ai-BCFAs) are the most abundant form of BCFA in
54 the Lm membrane, and the ability of Lm to thrive in cold temperatures is due in large part to
55 high ai-BCFA content that enhances membrane fluidity (15-17). To optimize membrane fluidity
56 in different environments, Gram-positive bacteria alter the ratio of ai-BCFAs to iso-BCFAs,
57 where ai-BCFAs contribute to higher fluidity due to positioning of the terminal methyl groups on
58 the acyl chains (18). Because BCFA synthesis depends on the acquisition and/or biosynthesis of
59 branched chain amino acids (BCAAs: Isoleucine, Leucine and Valine [Ile, Leu, Val]) (7, 19),
60 membrane remodeling and BCAA metabolism are tightly linked. While Lm is fully capable of
61 synthesizing BCAAs *de novo*, exogenous BCAAs are required for optimal growth due in part to

62 high demand for BCFAs in the membrane and the activity of a ribosome-mediated attenuator that
63 limits BCAA synthesis (20, 21). During infection, Lm replicates inside host cells where BCAAs
64 and other nutrients are limited and may be actively withheld from bacteria by host defense
65 mechanisms (22, 23). Therefore, the ability of Lm to acquire host BCAAs and to make *de novo*
66 BCAAs, especially Ile, to generate membranes with high BCFA levels is critical to Lm
67 pathogenesis.

68 Branched chain amino acid aminotransferase (BCAT) enzymes initiate bacterial BCFA
69 synthesis by converting BCAAs into branched chain α -keto acids. Downstream of BCAT,
70 branched chain α -keto dehydrogenase enzymes (BKD) produce acyl coenzyme A (CoA)
71 molecules that are the primers for fatty acid synthesis (Fig. 1A) (9). While BKD is essential for
72 BCFA metabolism and protection from host immune defenses such as antimicrobial peptides
73 (12, 13), the Lm BCAT IlvE is required for resistance to the compound *trans*-cinnamaldehyde, a
74 small molecule with anti-microbial properties (14, 24). Additionally, the transcriptional regulator
75 CodY, which senses BCAA and GTP levels, plays a major role in coordinating BCAA
76 metabolism with virulence gene expression (21, 25-28). Importantly, when Ile levels are high,
77 CodY inhibits *de novo* BCAA synthesis, and when Ile levels are low, this inhibition is relieved,
78 allowing the bacteria to synthesize vital BCAAs (7). Thus, the ability of Lm to sense and
79 regulate BCAA levels, particularly Ile, and to implement BCFA remodeling is an important
80 attribute for adaptation to changing environments, especially in stress conditions as found in the
81 mammalian host.

82 Due to the central requirement for Ile in promoting membrane integrity through
83 generation of ai-BCFAs and for engaging CodY regulatory activity, we hypothesized that
84 proteins involved in Ile metabolism are central to the ability of Lm to cause disease. Therefore,

85 we used a genetic approach to explore how the BCAT IlvE and the regulator CodY contribute to
86 membrane dynamics, growth and pathogenesis of Lm. Here we show that deficiency of either
87 IlvE or CodY can alter membrane fatty acid content, but bacteria lacking IlvE are very
88 susceptible to membrane stress and nutrient limitation and are less fit in *in vitro* and *in vivo*
89 infection models.

90

91 **RESULTS**

92

93 **Membrane anteiso-BCFA generation requires IlvE and relies on CodY for homeostasis in** 94 **stationary phase in nutrient restricted medium**

95 Isoleucine (Ile) is an essential metabolite for protein translation and for synthesis of the
96 high ai-BCFA membrane content of Lm (Fig. 1A), and the aminotransferase IlvE is predicted to
97 be the first enzyme that commits Ile into the biosynthetic pathway for odd-numbered (C15, C17)
98 ai-BCFAs. Low availability of Ile in the intracellular environment during infection is thought to
99 act as a signal for Lm to coordinate metabolism and virulence, mainly through the Ile-sensing
100 transcriptional regulator CodY (21, 26, 27). To characterize dynamics of Ile usage in BCFA
101 biosynthesis and virulence, we assessed deletion mutant strains lacking IlvE or CodY ($\Delta ilvE$ and
102 $\Delta codY$ mutants) (Table S1 and Methods).

103 Previously, an *ilvE* transposon-generated null mutant was shown to have extremely low
104 levels of ai-BCFAs when grown in rich, undefined BHI medium (14). Therefore, we predicted
105 that the $\Delta ilvE$ strain created for this study would have substantially lower levels of ai-BCFA
106 when grown in a nutrient-limited medium (Fig. 1A). Additionally, we predicted that the $\Delta codY$
107 mutant would generate ai-BCFA levels equivalent to WT, since eliminating CodY inhibition of

108 *de novo* BCAA synthesis should increase bacterial BCAA levels, resulting in ample building
109 blocks for ai-BCFAs. Note that recent RNAseq analysis showed that the expression of the Ile,
110 Leu, Val-production operon increased substantially in the $\Delta codY$ mutant in both rich medium
111 (BHI) and in nutrient-limited medium (29), but not when BCAAs were extremely limited;
112 moreover, the *codY* null mutation had no significant impact on *ilvE* transcription in any media
113 tested (T. A. Washington, A. L. Sonenshein and B. R. Belitsky, manuscript in preparation)
114 despite the fact that CodY has a relatively strong binding site upstream of *ilvE* (30), which could
115 also be a regulatory binding site for the locus upstream of *ilvE*. Therefore, to test the role of IlvE
116 and CodY in fatty acid metabolism, we measured total fatty acid content in WT, $\Delta ilvE$,
117 $\Delta ilvE::ilvE^+$ (*ilvE* complemented) and $\Delta codY$ strains grown to mid-logarithmic and stationary
118 phase in *Listeria* defined medium (LDM - contains seven amino acids including BCAAs) (29), a
119 nutrient-limited medium (Fig. 1B-C, Tables 1-2, Tables S3-S4).

120 The $\Delta ilvE$ strain contained significantly lower proportions of ai-BCFAs in the total fatty
121 pool compared to WT (Fig. 1B-C). During both culture phases, WT cells had greater than 80%
122 ai-BCFAs, while $\Delta ilvE$ cells had 30% ai-BCFAs in logarithmic phase and 21% ai-BCFAs in
123 stationary phase. Whereas WT cells had extremely low levels of iso-BCFAs (0.9 – 12%), the
124 $\Delta ilvE$ strain included substantial levels odd-numbered iso-C15 and iso-C17 fatty acids (37%) and
125 even-numbered iso-C14 and iso-C16 (26% to 33%) (Tables 1 and 2). This indicates that in the
126 absence of IlvE, Lm must incorporate the other BCAAs (Leu and Val) into BCFAs. The
127 complemented strain $\Delta ilvE::ilvE^+$ showed an almost identical fatty acid profile to WT in both
128 phases. Interestingly, the $\Delta codY$ mutant differed markedly from WT in stationary phase. Here,
129 ai-BCFAs made up 63% of the fatty acid profile, and even-numbered iso-BCFAs increased to
130 22% (ten-fold higher than WT). These results suggest that CodY may contribute to membrane

131 BCFA remodeling when salvageable nutrients are depleted, and may repress genes involved in
132 iso-BCFA synthesis during stationary phase.

133 We conclude that IlvE is a major driver for ai-BCFA generation during Lm growth in
134 nutrient-limited medium; however, bacteria lacking IlvE were still able to generate more than
135 20% ai-BCFAs, suggesting the presence of another aminotransferase that is able to incorporate
136 Ile into ai-BCFA. Additionally, we conclude that CodY is involved in BCFA homeostasis during
137 stationary phase in LDM.

138

139 **Bacteria lacking CodY harbor higher levels of BCAA compared to WT**

140 CodY is a sensor of BCAAs in Gram-positive bacteria, particularly Ile, and controls
141 BCAA synthesis when these important metabolites are at low levels (31, 32). We initially
142 hypothesized that bacteria lacking CodY would constitutively synthesize BCAAs in addition to
143 acquiring exogenous BCAAs, and therefore should be well positioned to generate sufficient
144 levels of ai-BCFAs regardless of growth phase. However, the observation that the $\Delta codY$ mutant
145 had lower levels of ai-BCFAs in stationary phase in LDM (Fig. 1C) prompted us to directly
146 measure levels of cell-associated BCAAs during growth in LDM. We therefore grew WT,
147 $\Delta codY$, $\Delta ilvE$ and $\Delta ilvE::ilvE^+$ strains in LDM to mid-logarithmic and stationary phase, removed
148 the extracellular medium, and assessed cell-associated BCAA content by mass spectrometry
149 (Fig. 1D-E). Unsurprisingly, $\Delta codY$ lysates contained higher levels of all three BCAAs relative
150 to WT during logarithmic growth, with Ile being the highest (~2.5-fold higher relative to WT),
151 confirming the role of CodY for BCAA synthesis during nutrient-restriction. Notably, we
152 observed approximately three-fold more Ile in stationary phase cultures for the $\Delta codY$ mutant
153 relative to WT, but similar levels of Leu and Val. Thus, although the $\Delta codY$ strain in stationary

154 phase contains more Ile available for ai-BCFA compared to WT, this strain does not match WT
155 levels of Ile incorporation into ai-BCFAs. These data suggest that CodY may play a role in
156 membrane ai-BCFA homeostasis during stationary phase through an as yet undefined
157 mechanism.

158 Since bacteria lacking IlvE showed a severe reduction in ai-BCFA content in LDM, we
159 hypothesized that the $\Delta ilvE$ mutant would harbor higher levels of cell-associated Ile during all
160 growth phases in LDM compared to WT due to the lack of incorporation of this amino acid into
161 ai-BCFAs. However, we observed similar levels of Ile in the $\Delta ilvE$ mutant and in WT during
162 logarithmic growth, and wide variability of cell-associated Ile in the $\Delta ilvE$ strain during
163 stationary phase (Fig. 1D-E). Also, Val was approximately half the level in the $\Delta ilvE$ mutant
164 compared to WT in logarithmic and stationary phase (Fig. 1D-E), while the Leu level was less
165 than half of WT only in stationary phase. These data suggest that when IlvE is lacking, Lm uses
166 Val and Leu for BCFA metabolism.

167

168 **Growth in BCAA-limiting conditions requires branched-chain aminotransferase IlvE**

169 While fatty acid analysis represents relative levels of lipid species in a population of
170 cells, these data do not reveal differences in growth rate between strains. Therefore, we
171 examined the contributions of IlvE and CodY to bacterial growth in nutrient replete Brain-Heart
172 Infusion medium (BHI) and in nutrient-limited LDM. All growth experiments were initiated
173 using bacteria grown to mid-logarithmic phase in LDM. We hypothesized that because the
174 absence of CodY normally contributes to increased BCAA biosynthesis during Ile limitation
175 (26), $\Delta codY$ bacteria would grow as well as, or better than, WT bacteria in LDM. We also

176 hypothesized that growth of the $\Delta ilvE$ mutant would be slower than WT in nutrient-limited
177 medium due to its severe reduction in ai-BCFAs, a major membrane component for Lm.

178 In BHI, both the $\Delta ilvE$ and the $\Delta codY$ mutants grew equivalently to WT, showing that
179 IlvE and CodY are not essential for Lm growth in a nutrient rich environment (Fig. 2A and Table
180 3). In LDM containing all three BCAAs at 100 $\mu\text{g/mL}$, the $\Delta ilvE$ strain grew slightly more
181 slowly than WT, whereas the $\Delta codY$ strain grew the same as, or slightly better than, WT (Fig.
182 2B). Although the $\Delta ilvE$ culture reached the same maximum density as WT in LDM, its doubling
183 time during logarithmic growth was about 1.7-fold longer than WT (Table 3). These data reveal
184 that ai-BCFA synthesis through IlvE contributes to bacterial growth rate when nutrients are
185 limited. In LDM, the $\Delta ilvE::ilvE^+$ complemented strain also grew more slowly than WT, despite
186 the fact that it was able to generate BCFA profiles similar to WT in this medium (Fig. 1B-C). We
187 therefore asked whether the *ilvE* gene is expressed at WT levels in the complemented strain.
188 Indeed, RT-qPCR of *ilvE* expression revealed lower transcript levels of this gene in the
189 complemented strain (Fig. 2C), particularly during exponential growth.

190 Fatty acid distributions (Fig. 1B-C) suggested that mutants lacking IlvE or CodY use Val
191 and Leu for synthesis of iso-BCFAs at higher levels than WT. Therefore, we asked how $\Delta ilvE$
192 and $\Delta codY$ strains would grow when one or all three of the BCAAs are lacking in the growth
193 medium, despite having the ability to synthesize all three BCAAs *de novo*. In LDM lacking all
194 three BCAAs, all four strains grew poorly, with WT and $\Delta ilvE::ilvE^+$ reaching the highest
195 optical density at 600 nm (OD₆₀₀) of ~0.4, compared to all strains reading ~0.6 in LDM when
196 all BCAAs were present (Fig. 2B versus Fig. 3A). Additionally, the $\Delta ilvE$ mutant exhibited large
197 variability when no BCAAs were supplied, while $\Delta codY$ grew the poorest (Fig. 2B versus Fig.
198 3A). The fact that the $\Delta codY$ mutant grew so poorly in medium with no exogenous BCAAs was

199 surprising considering that this mutant has no restriction on *de novo* synthesis of BCAAs. These
200 data support the semi-auxotrophic nature of Lm for BCAAs, highlighting the importance of
201 exogenous BCAAs for optimal growth and revealing a key role for IlvE and CodY when all
202 exogenous BCAAs are unavailable.

203 While IlvE is needed for enzymatic incorporation of Ile into BCFAs, CodY specifically
204 senses and binds cellular Ile (33, 34). Due to their specific relationships with Ile, we then asked
205 how $\Delta ilvE$ and $\Delta codY$ mutants would grow when exogenous Ile is lacking but when Val and Leu
206 are present. Interestingly, both $\Delta ilvE$ and $\Delta codY$ strains were similarly attenuated when only Ile
207 was lacking, reaching a lower maximum density compared to WT and $\Delta ilvE::ilvE^+$ strains (Fig.
208 3B). Again, this was unexpected for the $\Delta codY$ mutant, since we predicted that the $\Delta codY$ strain
209 would have no growth defect in the absence of Ile due to its higher cell associated Ile
210 concentrations (Fig. 1D-E). These results reveal a complex role for CodY in Ile sensing and
211 BCAA homeostasis. We conclude that both IlvE and CodY are required for optimal bacterial
212 growth when exogenous Ile is absent.

213 When either all three BCAAs or only Ile were absent in the growth medium (Fig. 3A-B),
214 the $\Delta ilvE$ and $\Delta codY$ mutants were attenuated for growth to a similar degree. However, in media
215 containing exogenous Ile but lacking either of the other two BCAAs (Leu or Val), the two
216 mutants revealed unique growth phenotypes (Fig. 3C-D). In LDM containing Ile and one other
217 BCAA (Val or Leu), the $\Delta codY$ mutant grew more robustly than WT, suggesting a dominant role
218 for Ile in Lm growth when CodY regulation is lacking. But the $\Delta ilvE$ mutant showed strict
219 requirements for Leu and Val in the presence of Ile. When only Leu was absent (ie, Ile and Val
220 present), the $\Delta ilvE$ mutant grew as it did in normal LDM (with all BCAAs, Fig. 2B) for about 12
221 hours, but reached stationary phase early and then had a decrease in OD600 (Fig. 3C). When

222 only Val was absent (ie, Ile and Leu present), the $\Delta ilvE$ strain was entirely unable to grow (Fig.
223 3D), revealing an absolute requirement for Val when exogenous Ile is not incorporated into ai-
224 BCFAs by IlvE. The IlvE complemented strain was able to eventually reach a maximum density
225 in stationary phase similar to that of WT in all of these conditions (Fig. 3A-D), albeit at a slightly
226 slower rate. Thus, when IlvE is not present, Lm has an increased dependence on Val and Leu for
227 growth. These data show that while CodY is tightly linked to Ile sensing and homeostasis, IlvE
228 activity plays a key role in cellular homeostasis when any of the individual BCAAs are lacking
229 exogenously. Collectively, these growth trends indicate that BCAA levels are controlled at
230 multiple levels in Lm.

231

232 ***Listeria* lacking IlvE exhibit decreased intracellular replication in macrophages and** 233 **reduced cell-to-cell spread**

234 Having established that IlvE and CodY play a role in generating membrane ai-BCFAs
235 and in promoting optimal growth in BCAA-limited environments, we asked whether these
236 proteins specifically contribute to Lm pathogenesis. We hypothesized that the $\Delta ilvE$ mutant
237 would be less efficient at intracellular growth in a cell culture infection model due to its
238 relatively slow growth during nutrient restriction. Previously, the $\Delta codY$ mutant strain has shown
239 different behaviors in various *in vitro* macrophage infections models (25, 28). Since the $\Delta codY$
240 mutant in this study grew robustly in nutrient-limited LDM (Fig. 2B), we predicted that it would
241 grow similarly to WT in primary macrophages. We also considered that the $\Delta codY$ mutant would
242 be deficient in cell-to-cell spread given its stationary phase reduction of ai-BCFAs.

243 We infected primary bone marrow-derived murine macrophages (BMDM) with Lm
244 strains prepared from mid-log phase LDM cultures and measured viable intracellular bacteria at

245 0, 4 and 8 hours post infection. At 4 and 8 h post-infection, intracellular growth of the $\Delta ilvE$
246 mutant was at least 1 log lower than WT (Fig. 4A). However, the $\Delta ilvE$ strain showed a growth
247 rate increase after 4 h, suggesting that this strain may be able to adapt to the intracellular
248 environment. The $\Delta ilvE::ilvE^+$ strain showed an intermediate phenotype, where intracellular
249 growth was less than that of WT but greater than that of the $\Delta ilvE$ mutant. WT and $\Delta codY$ strains
250 replicated within primary BMDM equivalently. We conclude that IlvE is required for optimal
251 growth in the nutrient-limited environment of macrophages, while CodY is not essential for
252 adaptation to intracellular growth within this cell type.

253 We then infected L929 cells with Lm strains prepared from mid-logarithmic LDM
254 cultures to assess the requirements for IlvE and CodY during multiple stages of intracellular
255 infection as measured by cell-to-cell spread (Fig. 4B-C). Plaques formed from infection with the
256 $\Delta ilvE$ mutant were approximately 66% the size of WT-infected plaques (Fig. 4C). The
257 complemented $\Delta ilvE::ilvE^+$ strain had a partially rescued plaque phenotype. We also observed
258 that plaques formed by the $\Delta codY$ mutant were not significantly different from those of WT (Fig.
259 4C). Taken together, these data demonstrate that IlvE is a critical component for Lm intracellular
260 growth and cell-to-cell spread.

261

262 **IlvE enhances bacterial survival in response to exogenous membrane stress**

263 Membrane BCFA content underlies Lm resistance to various cell stresses such as pH,
264 small molecules, low temperature, and host-specific antimicrobial mechanisms (8, 10, 12, 13, 16,
265 17, 35). As a foodborne pathogen, Lm must survive the acidic stomach environment and resist
266 damage from host molecules such as bile. To investigate the role of Ile-dependent BCFA
267 metabolism in protecting Lm membrane integrity, we tested the ability of $\Delta ilvE$ and $\Delta codY$

268 mutants to survive in the presence of membrane disrupting bile salts. We used a bile salt mixture
269 of cholic acid and deoxycholic acid, which are similar to the emulsifying bile acids in the
270 mammalian GI tract. We hypothesized that Lm lacking IlvE would be more susceptible to bile
271 salt stress than WT strains with a full complement of ai-BCFAs. Mid-logarithmic phase bacteria
272 grown in LDM were exposed to 0, 1, 2 and 4 mg/mL bile salts at 37°C for 30 min and measured
273 by counting CFU (Fig. 5A). WT Lm showed decreasing viability with increasing bile salt
274 concentration, with a reduction in viability of almost 2 logs from 0 to 4 mg/mL. The $\Delta ilvE$
275 mutant strain showed a consistent 1-log decrease in viability compared to WT at each
276 concentration. The complemented strain $\Delta ilvE::ilvE^+$ was slightly less viable at 1 mg/mL, but
277 was similar to WT at 2 and 4 mg/mL. Lastly, the $\Delta codY$ mutant showed susceptibility to bile salt
278 stress similar to that of WT. We therefore conclude that IlvE promotes resilience against
279 membrane stress, likely through its role in populating the Lm membrane with ai-BCFAs.

280

281 **IlvE is required for optimal infection of C57BL/6 mice**

282 While *in vitro* infections can shed light on the intracellular growth capabilities of Lm,
283 they do not illuminate the more complex physiological dynamics of an animal infection. We
284 hypothesized that IlvE and CodY would contribute to pathogenesis in a mouse model of
285 infection, and that the IlvE would have more of an impact due to its constitutive role in
286 membrane fatty acid synthesis. We used a competitive index (CI) assay to measure the fitness of
287 Lm strains in C56BL/6 mice (36). Briefly, we injected mice intraperitoneally with a WT Lm
288 strain that is resistant to erythromycin (WT-erm^r) combined with a mutant strain (test strain-
289 erm^s) in a 1:1 mixture (WT-erm^r : test strain-erm^s). After 48 h, spleens and livers were removed
290 and bacteria plated on LB-agar with or without antibiotic to discern resistant (WT^R) versus

291 sensitive (test strain^S) bacteria and calculated the CI. The lower the CI, the less “competitive” the
292 test strain was compared to WT during infection.

293 In both spleen and liver (Fig. 5B-C), substantially fewer $\Delta ilvE$ bacteria were recovered.
294 The mean CI for the $\Delta ilvE$ strain in both organs was less than 0.2, indicating severe attenuation
295 in mice. Although the IlvE complemented strain grew better in mice than the deletion mutant, it
296 was recovered at lower levels than WT, suggesting that robust expression of *ilvE* is necessary for
297 optimal survival in a whole animal. Lastly, while bacteria lacking CodY showed a CI of ~0.5 in
298 mouse spleen, a CI of 0.1 in liver suggests that the liver environment is a more restrictive growth
299 milieu for the $\Delta codY$ mutant. Overall, these data underline a major role for ai-BCFA metabolism
300 through IlvE for all aspects of Lm growth and virulence, with CodY playing a major role mainly
301 during Ile restriction and severe nutrient restriction.

302

303 **DISCUSSION**

304

305 The plasma membrane of *Listeria monocytogenes* (Lm) is a major structure of the
306 bacterial cell surface and a key interface with host cells (3). Understanding how Lm assembles
307 and remodels membranes to thrive within the host is key to our understanding of this important
308 pathogen. In this study, we explored how two Isoleucine (Ile) responsive proteins, the
309 aminotransferase IlvE and the regulator CodY, contribute to growth, plasma membrane
310 composition, and virulence of Lm. Our findings reveal a crucial role for IlvE in generation of
311 membrane ai-BCFAs, robust growth during nutrient limitation, protection from membrane stress,
312 and virulence in cell culture and in mice. Additionally, our work shows that CodY is involved in
313 modulating membrane ai-BCFA content during stationary phase, and that exogenous Ile is

314 required for bacterial growth when CodY is lacking. However, we observed that CodY is
315 relevant in the nutrient environment of the liver, but contributes less to bacterial fitness in the
316 spleen where *Lm* primarily replicates in macrophages. Collectively, our findings point to a
317 complex role for Ile usage through IlvE in promoting ai-BCFA membrane composition and also
318 highlight an important relationship between BCAA and ai-BCFA metabolic pathways for *Lm*
319 pathogenesis.

320 Anteiso-BCFAs are the major component of the *Lm* plasma membrane, and the
321 aminotransferase IlvE incorporates Ile into ai-BCFA biosynthesis (Fig. 1) (15, 18). Our main
322 finding that IlvE is a crucial element of *Lm* biology and virulence is supported first by the
323 observation that bacteria lacking this enzyme ($\Delta ilvE$) are severely restricted for growth under
324 multiple conditions of nutrient limitation. Since *Lm* is an intracellular pathogen, and the
325 intracellular environment is a nutrient-restricted medium (23), *Lm* must have strategies for
326 acquiring or synthesizing critical metabolites, such as BCAAs, during infection (2, 23). Notably,
327 IlvE was not required for optimal growth in rich-undefined medium, showing that Ile
328 incorporation into ai-BCFAs is not necessary when exogenous nutrients are in great abundance.
329 Rather, IlvE was critically needed for axenic growth during BCAA limitation, in particular when
330 only exogenous Valine or Leucine was unavailable, underscoring the central importance of Ile
331 for membrane metabolism.

332 Our results also highlight the complex nature of BCAA metabolism in *Lm*, which is
333 somewhat curious, since these bacteria are able to synthesize BCAA endogenously but still
334 require exogenous BCAAs for optimal growth (22, 26). *Lm* expresses BCAA biosynthetic genes
335 during infection (26), indicating BCAA limitation within cells. Recent investigation into this
336 phenomenon has revealed that while the Ile-binding regulatory protein CodY inhibits BCAA

337 synthesis when Ile is abundant, the bacteria also limit BCAA synthesis through Rli60 even when
338 CodY inhibition is relieved during Ile restriction, as within the host (21). These opposing
339 processes allow the bacteria to fine-tune Ile levels in order to satisfy BCAA requirements for
340 growth while also allowing virulence gene expression (21). We showed that bacteria lacking
341 CodY or IlvE were severely attenuated for growth when Ile was not available in the medium,
342 highlighting a central role for exogenous Ile during growth. But bacteria lacking CodY harbored
343 more cell-associated BCAAs during growth in nutrient-limited LDM, strongly suggesting a
344 constitutive increase in endogenous BCAA synthesis when CodY inhibition is completely
345 lacking. Thus, the $\Delta codY$ mutant's poor growth in the absence of Ile was unexpected, since these
346 bacteria have a greater Ile pool most likely due to *de novo* synthesis. Moreover, the highly robust
347 growth of the $\Delta codY$ mutant when exogenous Ile and one other BCAA were available
348 underscores a vital role for exogenous Ile in the fine-tuning of BCAA metabolism through
349 CodY, perhaps through involvement in controlling BCAA transport as in *Bacillus subtilis* (27).
350 Collectively, these findings suggest that within the nutrient-restricted intracellular environment,
351 Lm must be able to access sufficient Ile for ai-BCFA synthesis through IlvE activity, but must
352 also sense relative Ile limitation such that CodY metabolic inhibition is relieved to support
353 endogenous BCAA generation for optimal growth.

354 Another line of evidence pointing to the critical nature of IlvE in Lm biology is its major
355 role in supporting production of resilient membranes during nutrient restriction at biological
356 temperatures (37°C). The importance of ai-BCFA membrane content for resistance to cold has
357 been well established for Lm, and indeed Lm is able to modulate the percentage of ai-BCFAs in
358 response to temperature, salinity, and pH (8, 15-17). However, the Lm membrane is always
359 predominantly made up of Ile-primed odd-numbered ai-BCFAs, emphasizing the central

360 importance of the Ile-to-ai-BCFA biosynthetic pathway for this pathogen. Our demonstration
361 that bacteria lacking IlvE have greatly reduced ai-BCFA content and are sensitive to bile salts
362 directly implicates Ile usage by IlvE as a major player in synthesizing resilient bacterial
363 membranes. Within host cells, Lm is subjected to a variety of membrane-targeting host defenses
364 such as antimicrobial peptides, and ai-BCFAs have been shown to be important for resistance to
365 these mechanisms when the enzyme branched-chain α -keto acid dehydrogenase (BKD),
366 downstream of IlvE, is lacking (13). While those stresses are experienced by Lm inside host
367 cells, Lm is a foodborne pathogen, and so must also survive the low pH of the stomach and the
368 high concentration of bile acids in the small intestine (37, 38). A lifestyle-specific evolution of
369 ai-BCFA metabolism is evident in the Gram-positive dental pathogen *Streptococcus mutans*,
370 which requires IlvE for acid tolerance, such as might be experienced in the oral cavity (39).
371 Thus, the contribution of IlvE for bile salt resistance in Lm reveals that a major need for Ile and
372 ai-BCFAs evolved as a fundamental physiological feature for surviving stress within the diverse
373 environments that this pathogen experiences. Further exploration into the mechanism of bile salt
374 resistance may reveal membrane structural features and bile salt transport mechanisms as playing
375 key roles.

376 The central importance for IlvE was also revealed by the severe attenuation of the $\Delta ilvE$
377 strain in cell culture and in a mouse model of listeriosis. As mentioned previously, the
378 intracellular milieu is nutrient-restricted and a site of antimicrobial assault. Thus, the decrease in
379 intracellular growth of Lm lacking IlvE after four hours of macrophage infection is likely due to
380 enhanced microbial killing, as was seen in the BKD mutant (13). However, it should be noted
381 that the $\Delta ilvE$ mutant established growth macrophages between 4 and 8 hours, which may
382 indicate a regulatory stress response when Ile incorporation into ai-BCFAs is compromised. This

383 observation, combined with the fact that the $\Delta ilvE$ mutant still had 20-30% ai-BCFAs during
384 growth in LDM, hints at the presence of another transaminase that can use Ile for ai-BCFA
385 synthesis. Different from what we observed, an Lm mutant lacking *ilvE* in a different parental
386 strain background was almost entirely lacking in ai-BCFAs when grown in rich medium, well
387 under 10% of fatty acid content (14), and this could mean that Lm has several regulatory
388 strategies for membrane homeostasis depending on the nutritional content of the growth medium.
389 However, the amount of ai-BCFAs that we observed in the absence of IlvE was not sufficient for
390 full virulence in a whole animal, highlighting the necessity of IlvE mediated ai-BCFA synthesis
391 for membranes during infection.

392 Lastly, our results also shed light on the complexity of CodY regulation, which in
393 addition to BCAA metabolism, is also known to be involved in nitrogen and carbon assimilation
394 and regulation of Lm virulence gene expression (21, 25, 27). Previous studies of $\Delta codY$ mutants
395 in *in vitro* macrophage models have shown different results, where CodY was not required for
396 growth in a transformed macrophage line (25), but was required for optimal growth within
397 primary macrophages (26). In our study, we did not observe a defect in growth within primary
398 macrophages for the $\Delta codY$ mutant. But note that while the $\Delta codY$ mutant had an identical fatty
399 acid profile to WT during logarithmic growth, it showed a significant reduction in ai-BCFAs
400 during stationary phase: and for our macrophage experiments, we used $\Delta codY$ cultures that were
401 prepared at mid-logarithmic phase grown in nutrient-limited medium. This parameter may have
402 poised the bacteria to be more resistant to macrophage killing during the brief, 8-hour duration of
403 the experiment, and this possibility is currently being explored. Regardless, our data are the first
404 to describe a role for CodY in Lm pathogenesis in a whole animal model, where the $\Delta codY$
405 mutant was attenuated predominantly in the mouse liver.

406 In this study, we determined that the branched-chain amino acid transaminase IlvE plays
407 a central role in the membrane dynamics of *L. monocytogenes* and is necessary for robust
408 replication during intracellular infection *in vitro* and *in vivo*. Collectively, our findings highlight
409 an intricate connection between BCAA and BCFA metabolism, and further support a model
410 where Ile is a key metabolite for bacterial growth and virulence, in particular through the activity
411 CodY. Future investigation into how Lm remodels its membrane during interactions with the
412 host will expand our understanding of how pathogens use this defining cellular structure to
413 enhance infection.
414

415 **FIGURE LEGENDS**

416

417 **Figure 1. Changes in Fatty Acid and BCAA content in Lm lacking *IlvE* or *CodY*.** (A)

418 Simplified overview of branched chain fatty acid (BCFA) biosynthesis in Gram-positive bacteria

419 (based on detailed diagram in (9)) showing pathways that incorporate branched chain amino

420 acids (BCAAs: Ile, Leu & Val). Red X represents points in pathways where deletion mutants

421 were used in this study. Colored arrows indicate pathways of individual BCAAs that are

422 incorporated into final BCFA isoforms (18). Purple text = enzyme names. (B and C) Graphs

423 represent the relative amounts of the major fatty acids as a percentage of total fatty acids

424 contained in Lm cultures of WT, $\Delta ilvE$, $\Delta ilvE::ilvE^+$ and $\Delta codY$ strains grown in nutrient

425 limiting medium (LDM) to (B) mid-logarithmic and (C) stationary phase. Graphs represent

426 combined data from three independent experiments. Graphs shown here and data in Tables 2 and

427 3 are the combined quantities of odd numbered (C15 and C17) or even-numbered (C14 and C16)

428 BCFAs. Individual numbered species (e.g., ai-C15 only) and all other fatty acids are in

429 Supplemental Tables S3 and S4. (D and E). Cultures of WT, $\Delta ilvE$, $\Delta ilvE::ilvE$ and $\Delta codY$

430 strains grown in LDM to (D) mid-logarithmic and (E) stationary phase were analyzed by mass

431 spectrometry. Concentrations of BCAAs were normalized to total protein content and are shown

432 as ratios relative to WT. Error bars show the range of fold difference compiled from 2

433 independent experiments.

434

435 **Figure 2. Growth of $\Delta ilvE$ and $\Delta codY$ mutants in rich and nutrient-limited medium.**

436 Bacterial growth of WT (circles), $\Delta ilvE$ (triangles), $\Delta ilvE::ilvE^+$ (inverted triangles), and $\Delta codY$

437 (squares), was analyzed on a Bioscreen instrument. Samples were inoculated from recovered

438 frozen cultures that had been prepared in LDM to mid-logarithmic phase. Optical Density at 600
439 nm (OD600) was measured for 24 hours at 37°C with shaking. Experiments include growth in
440 (A) Rich medium = Brain Heart Infusion (BHI) and (B) LDM containing amino acids at 100
441 µg/mL. Data are compiled from three independent experiments with three technical replicates
442 per experiment. Each point is the mean with error bars representing the Standard Deviation. (C)
443 RT-qPCR analysis of *ilvE* expression in Lm grown in LDM to logarithmic (left) and stationary
444 (right) phase.

445

446 **Figure 3. Growth of Lm in LDM with variable exogenous BCAAs.** Bacterial growth of WT
447 (circles), $\Delta ilvE$ (triangles), $\Delta ilvE::ilvE^+$ (inverted triangles), and $\Delta codY$ (squares), performed as
448 in Figure 2, but in LDM containing (A) no BCAAs, (B) no Ile (Val & Leu only), (C) no Leu (Ile
449 & Val only), and (D) no Val (Ile & Leu only). Data are compiled from three independent
450 experiments with three technical replicates per experiment. Each point is the mean with error
451 bars representing standard deviation.

452

453 **Figure 4. IlvE is required for optimal growth in macrophages and for cell-to-cell spread in**
454 **cell culture.** (A) Total CFU from survival assays of Lm infection of Bone Marrow Derived
455 Macrophages (BMDM) assessed at 0.5, 4 and 8h post-infection. Data are compiled from three
456 independent experiments showing mean and standard deviation. MOI = 1. (B-C) Plaque assay of
457 Lm grown in L9 fibroblasts. (B) Representative image of plaques formed by WT & $\Delta ilvE$
458 bacteria after 48h growth. (C) Average plaque diameters from experiments that included WT,
459 $\Delta ilvE$ and $\Delta ilvE::ilvE^+$ (left) or WT and $\Delta codY$ (right). Numbers below graphs are the mean

460 plaque diameter with standard deviation compiled from three independent experiments. Two-
461 tailed *t*-test comparing mutants to WT, **** $P < 0.0001$; ns = not significant.

462

463 **Figure 5. *IlvE* is required for resistance to membrane stress in response to bile salts and for**

464 **survival in a mouse model of listeriosis.** (A) Log-phase bacteria grown in LDM were added to

465 PBS with 0, 1, 2 and 4 mg/mL Bile Salts (Cholic acid-Deoxycholic acid sodium salt mixture)

466 and incubated at 37°C for 30 minutes. Input for all samples was $\sim 10^7$ CFU/mL. Data are

467 compiled from three independent experiments. One-way ANOVA (non-parametric) with Dunn's

468 multiple comparisons post-test comparing mutant strains to WT. ns = not significant; * $P < 0.05$;

469 *** $P < 0.001$; **** $P < 0.0001$. (B and C) Female C56BL/6 mice were infected with a 1:1 mixture

470 of erythromycin-sensitive test strains and erythromycin-resistant WT strain via intraperitoneal

471 injection. After 48h infection, (B) spleens and (D) livers were harvested and assessed for viable

472 CFU and competitive index (CI) was calculated as the ratio of Sensitive/Resistant CFU. Data

473 represent two independent experiments with total $n=7$ mice for all strains except WT, which was

474 $n=8$. LOD = limit of detection.

475

476 **TABLES**

477

478 **Table 1. Fatty Acid Content of *L. monocytogenes* during Logarithmic Growth in LDM**

	Percent of Total Fatty Acid Content – Logarithmic Growth			
	Mean Percent (SD)			
	WT	<i>ΔilvE</i>	<i>ΔilvE::ilvE⁺</i>	<i>ΔcodY</i>
Other	0.95 (0.20)	7.41 (3.58)	6.72 (9.05)	1.91 (0.54)
anteisoC15:C17	88.56 (0.30)	****29.67 (13.54)	84.67 (8.76)	86.41 (1.44)
isoC15:C17	9.60 (0.30)	****37.06 (6.15)	6.85 (1.80)	7.43 (1.36)
isoC14:C16	0.89 (0.11)	****25.86 (9.50)	1.76 (0.61)	4.24 (0.86)

479 Two-Way ANOVA using Dunnett's Multiple Comparisons Test (compare rows within columns)

480 compared to Wild Type (WT). **** $P < 0.0001$.

481

482 **Table 2. Fatty Acid Content of *L. monocytogenes* during Stationary Phase in LDM**

	Percent of Total Fatty Acid Content – Stationary Phase			
	Mean Percent (SD)			
	WT	$\Delta ilvE$	$\Delta ilvE::ilvE$	$\Delta codY$
Other	1.65 (0.44)	*8.86 (1.85)	1.53 (0.21)	4.84 (3.27)
anteisoC15:C17	83.87 (2.76)	****21.06 (4.14)	85.55 (3.53)	****62.75 (8.89)
isoC15:C17	12.26 (2.09)	****36.87 (1.23)	8.32 (2.23)	10.44 (2.69)
isoC14:C16	2.22 (0.66)	****33.22 (5.51)	4.60 (3.75)	****21.97 (3.03)

483 Two-Way ANOVA using Dunnett's Multiple Comparisons Test (compare rows within columns)

484 compared to Wild Type (WT). * $P < 0.05$; **** $P < 0.0001$

485 Data are combined from n = 3 experiments

486

487 **Table 3. ¹Doubling times of *L. monocytogenes* strains in small volume growth analysis in**
 488 **rich (BHI) and nutrient-limiting (LDM) medium.**

	WT	$\Delta ilvE$	$\Delta ilvE::ilvE^+$	$\Delta codY$
	Mean (SD) in minutes			
BHI	65.9 (5.9)	71.0 (2.3)	59.5 (18.1)	63.8 (3.3)
LDM	118.5 (5.9)	196.1 (17.0)	204.9 (13.9)	110.9 (6.5)

489 ¹Calculated per (40). Data are combined from n = 4 independent experiments combined

490

491

492 MATERIALS AND METHODS

493

494 Bacteria, cell culture and media

495 *Listeria monocytogenes* strains used in this study are listed in Supplemental Table S1.
496 Wild Type (WT) *L. monocytogenes* is 10403S and all mutants indicated were created using this
497 parental background. Bacteria were grown in either BHI or LDM (29). Briefly, LDM contains
498 the following final concentrations: 50 mM MOPS/2 mM K₂HPO₄ (pH 7.5), 0.02%
499 MgSO₄*7H₂O, 0.5 mM Ca(NO₃)₂, 0.2% NH₄Cl, 0.5% Glucose, 0.004% FeCl₃/Na₃-
500 Citrate*2H₂O, 0.5 µg/mL Riboflavin, 1 µg/mL Thiamine-HCl, 0.5µg/mL Biotin, 0.005µg/mL
501 Lipoic Acid, 100 µg/mL of the amino acids Isoleucine, Leucine, Valine, Methionine, Arginine,
502 Histidine-HCl, Cysteine-HCl. Bone marrow derived murine macrophages (BMDM) were
503 isolated from wild type C57BL/6 mice per standard conditions and frozen in liquid nitrogen. The
504 day before *in vitro* infections, cells were thawed, spun by centrifugation, and resuspended in
505 fresh DMEM-10 (Gibco DMEM #11995-065 with 4.5 g/L D-Glucose and 110 mg/L Sodium
506 Pyruvate, 10% Fetal Bovine Serum [HyClone], 1% HEPES [Gibco 1M 15630-080], 1% Non-
507 Essential Amino Acids [Gibco 100X 11140-050] and 1% L-Glutamine [Gibco 200 mM 25030-
508 081]).

509

510 Creation of mutant strains

511 The markerless, in-frame $\Delta ilvE$ mutant was constructed using the pKSV7 recombination
512 plasmid (41) per standard conditions such that 1,020 base pairs of the coding sequence were
513 excised. The gene LMRG_02078 sequence in biocyc.org was used for mutant deletion method
514 design. The complemented strain $\Delta ilvE::ilvE^+$ was constructed using the $\Delta ilvE$ parental strain by

515 inserting the coding sequence for LMRG_02078, including 500 base pairs upstream of the start
516 codon, using the shuttle integration vector pPL2 (42) per standard procedures. Note that two
517 independent complemented strains were constructed, one with a FLAG tag inserted at the 5' end
518 of the gene ($\Delta ilvE::ilvE$ -FL). Primer sequences are listed in Supplementary Table S2.

519 The *codY* null mutant was created by insertion-deletion of a *spc* gene originating from the
520 plasmid pJL73 (43). The entire *codY* coding sequence was replaced, in the same orientation, by
521 the spectinomycin resistance cassette using the shuttle vector pMAD (44) per standard
522 procedures. A more detailed description of construction of the *codY* null mutant, including
523 primer sequences, will be included in an upcoming manuscript prepared by T.A. Washington, B.
524 R. Belitsky, and A. L. Sonenshein.

525

526 **Growth and survival analysis**

527 Cultures of all strains were grown in liquid LDM or BHI medium to Optical Density 600
528 nm (OD₆₀₀) 0.40 – 0.50 and frozen at -80°C in 1 mL aliquots. Frozen stocks were titered for
529 viable bacteria, and on the day of experiments, aliquots were thawed at 37°C for five minutes
530 and shaken at 37°C in fresh medium for 30 minutes. Bacteria were then diluted 1:10 into fresh
531 medium and added to a Bioscreen C honeycomb 100-well plate in a 300 µL volume in triplicate.
532 Plates were incubated at 37°C for 24 hours with constant shaking at medium speed. OD₆₀₀
533 readings were taken every 15 minutes on the Bioscreen C instrument. Growth was graphed in
534 Prism. Doubling times were calculated per (40) as follows: $n = [\log_{10}(\text{high OD}_{600}) - \log_{10}(\text{low}$
535 $\text{OD}_{600})] / 0.3010$ (where OD₆₀₀ values are from exponentially dividing cells). Doubling time =
536 time between OD₆₀₀ / n.

537 Survival during exposure to Bile Salts was performed as follows. Strains were thawed
538 from frozen stocks of bacteria grown to mid-log (OD600 ~0.45) in LDM, added to fresh LDM,
539 and shaken at 37°C for 30 min. Bacteria (~10⁷ bacteria/mL) were then added to 4 mL of PBS
540 containing Bile Salts (Sigma #48305) at 0, 1, 2 and 4 mg/mL. Tubes were shaken at 37°C for 30
541 min and then serially diluted with plating on LB-agar plates.

542

543 **Fatty Acid Content**

544 Bacteria were grown in LDM to mid-log (OD600 0.4-0.5) and stationary phase (OD600
545 0.9 – 1.1), spun by centrifugation, washed 1X with PBS, spun again, and frozen at -20°C. Cells
546 were sent on dry ice to Microbial ID for Whole Cell Fatty Acid Analysis. Experiments were
547 performed three times, independently. Results were combined and graphed in Prism 7 or 8 with
548 standard deviation.

549

550 **Amino Acid Analysis**

551 Strains grown on BHI agar were used to inoculate fresh liquid LDM and were grown to
552 mid-log (OD600 0.45 – 0.55) or stationary phase (OD600 > 0.8). Cultures (12 or 10 mL) were
553 spun by centrifugation and washed one time with 2 mL 150 mM Ammonium Acetate. Cells were
554 again spun by centrifugation, the supernatant was removed, and cell pellets were snap frozen in a
555 dry ice-ethanol bath. Cells were stored at -80°C until delivery to the Michigan Regional
556 Comprehensive Metabolomics Resource Core (MRC2) at the University of Michigan and
557 analyzed for total amino acid content as follows. Briefly, cells were homogenized in 200 µL of
558 extraction solvent (20% water, 80% 1:1:1 methanol:acetonitrile:acetone) containing 13C or 15N-
559 labeled amino acid internal standards. Samples were incubated at 4°C for 10 min, vortexed, and

560 spun by centrifugation at 4°C for 10 min at 14,000 rpm. Samples were diluted 20-fold and
561 transferred to autosampler vials for mass spectrometric analysis. Chromatographic separation of
562 underivatized amino acids was done using an Intrada Amino Acid column (Imtakt USA). Mobile
563 phases for separation were water:acetonitrile (8:2 v/v) containing 100 mM ammonium formate
564 (solvent A) and acetonitrile with 0.3% formic acid (solvent B). Flow rate was 0.6 ml/min, and
565 sample injection volume was 5 µL. ESI-MS/MS data acquisition was performed in positive ion
566 mode on an Agilent 6410 LC-MS with MRM transitions programmed for both labeled and
567 unlabeled internal standards. A pooled plasma reference sample and “test pooled” sample were
568 included as quality controls. Calibration standards were prepared containing all 20 proteinogenic
569 amino acids at various concentrations and analyzed in replicate along with test samples. LC-MS
570 data were processed using MassHunter Quantitative Analysis software version B.07.00. Amino
571 acids were quantified as pmol/million cells (ascertained by serial dilution and plating) and as
572 pmol/µg total protein using linear calibration curves generated from the standards listed above.
573 All peak areas in samples and calibration standards were first normalized to the peak area of the
574 internal standards.

575

576 **In vitro bone marrow derived macrophage infections**

577 Bone marrow derived macrophages (see Bacteria, cell culture and media) were thawed
578 and plated in 24-well tissue culture plates with 2.5×10^5 cells/well and allowed to recover
579 overnight (~18 hours) at 37°C/5% CO₂. Following recovery, medium was removed and replaced
580 with 500 µL of DMEM (no antibiotics) containing bacteria (prepped as in Growth Curve
581 analysis) at Multiplicity of Infection (MOI) of one. BMDM with bacteria were incubated for 30
582 min at 37°C/5% CO₂ and then washed three times with warm DPBS++ (+Calcium and

583 +Magnesium Chloride – Gibco 14040). One mL fresh DMEM-10 with Gentamicin (50 µg/mL)
584 was added to cells to kill extracellular bacteria. Cells were incubated for 0, 4 and 8 hours. At
585 time of harvest, cells were washed one time with DPBS++ and then incubated in 1 mL of 0.1%
586 Triton-X for 5 min. Cells were removed by scraping and pipetting and then transferred to 3.5
587 mL sterile double distilled water and vortexed for 10s. 500 µL 10X PBS was added to promote
588 bacterial integrity. Samples were either directly plated or serially diluted and then plated on LB-
589 agar plates and incubated overnight at 37°C. Experiments were done with three technical
590 replicates per experiment on three separate days. Data were compiled and graphed in Prism 7 or
591 8.

592

593 **In vivo mouse experiments**

594 Mouse experiments were performed with 6 to 7-week-old female BALB/c mice. Bacteria
595 were grown in BHI to OD600 0.50 and frozen in 1 mL aliquots. On the day of experiments,
596 bacteria were thawed and resuspended in 3 mL of fresh BHI and incubated with shaking for 1.5
597 hours at 37°C. Bacteria were pelleted by centrifugation, washed one time with sterile PBS,
598 pelleted again, and then resuspended in 1 mL sterile PBS. Bacteria were serially diluted and
599 plated to ascertain original titer. Bacteria were then combined in the following strain
600 combinations in a 1:1 ratio to attain a concentration of 10^5 CFU of each strain per 100 µL of
601 PBS. WT-erm^r:WT-erm^s; WT-erm^r: $\Delta ilvE$ -erm^s; WT-erm^r: $\Delta ilvE::ilvE^+$ -erm^s; WT-erm^r: $\Delta codY$ -
602 erm^s. Mice were injected peritoneally with 100 µL of bacterial inoculum. Inocula for all strain
603 combinations were serially diluted and plated on LB-agar and LB-agar-erythromycin plates to
604 measure INPUT concentrations. Mice were then housed for 48 hours in biocontainment rooms
605 before sacrifice and harvest of spleens and livers. Spleens were homogenized in 1 mL sterile

606 PBS with 1.0 mm Zirconia/Silica beads (BioSpec 11079110z), and livers were homogenized in 5
607 mL sterile PBS with a handheld tissue homogenizer. Samples were serially diluted and plated in
608 duplicate on both non-antibiotic containing LB agar plates and LB agar plates containing
609 erythromycin. CFU/mL per gram of tissue were obtained for all samples sets post-harvest
610 (OUTPUT), and the number of antibiotic sensitive and resistant bacteria were obtained by [CFU
611 on LB plates] minus [CFU on erythromycin-containing plates] = sensitive bacteria. Ratios of
612 erm-sensitive to erm-resistant bacteria for both INPUT and OUTPUT were calculated, and the
613 Competitive index was calculated as OUTPUT ratio / INPUT ratio (36). Mouse experiments
614 were performed on two separate days with n = 3 and n = 4 mice per experiment.

615

616 **L929 Plaque Assay**

617 L929 cells (mouse fibroblast cells) were grown in DMEM-10 medium (see “cell culture”
618 above) medium and plated in 6-well tissue culture plates at 10^5 cells/well at 37°C/5% CO₂ until
619 cells were almost 100% confluent. On the day of experiments, medium was removed and
620 replaced with fresh medium containing Lm at MOI = 30, incubated for 1h at 37°C/5% CO₂, and
621 washed three times with DPBS++ (plus ions). A 1:1 agarose (1.4%):2X DMEM overlay was
622 then added to each well. Plates were incubated at 37°C/5% CO₂ until plaques were visible.
623 Neutral red mixed with PBS was added to the wells for 1 h to allow for visualization of plaques.
624 After plaques were visible, images of each plate were taken (with a ruler included in the picture),
625 and plaque diameter was measured in ImageJ using the ruler in millimeters (mm) as a standard.
626 At least ten plaques were measured in three separate wells for each of three independent
627 experiments performed on different days. Data were compiled, the mean and standard deviation

628 calculated, and the Student's unpaired, two-tailed *t*-test was used to compare mutant strains to
629 WT. Data are shown as the mean plaque diameter percentage of WT per each experiment.

630

631 **Gene expression via RT-qPCR**

632 Bacteria were grown in LDM to mid-log (OD₆₀₀ 0.4-0.5) and stationary phase (OD₆₀₀
633 0.9 – 1.1) and then spun by centrifugation. After lysis by bead-beating, total bacterial RNA was
634 isolated using either the “Quick-RNA Fungal/Bacterial Miniprep” (Zymo Research #R2014) or
635 the “FastRNA Blue Kit” (MPBio #116025-050). RNA was extracted per manufacturers’
636 protocols and treated with DNase. RNA was precipitated using isopropanol and quantitated on a
637 Nanodrop ND-1000 spectrophotometer. cDNA was made using 250 ng RNA with Invitrogen
638 SuperScript II RT per the manufacturer’s protocol. No-RT controls were created for each RNA
639 sample by omitting RT in cDNA prep. To measure relative gene expression, 1 μL of cDNA was
640 used for SYBR green qPCR using Brilliant II SYBR Green QPCR Master Mix with Low ROX
641 (Agilent #600830) in Bio-Rad Hard Shell PCR 96-well plates (Bio-Rad #64201794) with all
642 cDNA preps done in duplicate, including all no-RT controls. Plates were run on a Bio-Rad
643 CFX96 Real-Time System Thermal Cycler with the following protocol: 10 min at 95°C, 40X
644 cycle of [10s 95°C; 45s 53°C; 1 min 72°C], 30s 95°C, 30s 65°C, 30s 95°C. The *L.*
645 *monocytogenes* genes *ilvE* (*LMRG_02078*) and *gyrA2* were measured, and *gyrA2* was used as a
646 housekeeping gene for data normalization. Primer sequences are listed in Supplemental Table
647 S2. Changes in gene expression were calculated per the $2^{-\Delta\Delta Ct}$ method (45) comparing mutants
648 to WT.

649

650 **ACKNOWLEDGMENTS**

651 This work was funded by NIH R01 AI109048. The authors acknowledge Microbial ID for Fatty
652 Acid analysis and the Michigan Regional Comprehensive Metabolomics Core at the University
653 of Michigan for amino acid analysis. Some Illustrations were partially generated in Biorender
654 (www.biorender.com).

655

656

657

658 **REFERENCES**

- 659 1. **Freitag NE, Port GC, Miner MD.** 2009. *Listeria monocytogenes* - from saprophyte to
660 intracellular pathogen. *Nat Rev Microbiol* **7**:623-628.
- 661 2. **Radoshevich L, Cossart P.** 2018. *Listeria monocytogenes*: towards a complete picture of
662 its physiology and pathogenesis. *Nat Rev Microbiol* **16**:32-46.
- 663 3. **King JE, Roberts IS.** 2016. Bacterial Surfaces: Front Lines in Host-Pathogen
664 Interaction. *Adv Exp Med Biol* **915**:129-156.
- 665 4. **Pizarro-Cerda J, Cossart P.** 2018. *Listeria monocytogenes*: cell biology of invasion and
666 intracellular growth. *Microbiol Spectr* **6**.
- 667 5. **Carvalho F, Sousa S, Cabanes D.** 2014. How *Listeria monocytogenes* organizes its
668 surface for virulence. *Front Cell Infect Microbiol* **4**:48.
- 669 6. **Raines LJ, Moss CW, Farshtchi D, Pittman B.** 1968. Fatty acids of *Listeria*
670 *monocytogenes*. *J Bacteriol* **96**:2175-2177.
- 671 7. **Kaiser JC, Heinrichs DE.** 2018. Branching Out: Alterations in Bacterial Physiology and
672 Virulence Due to Branched-Chain Amino Acid Deprivation. *MBio* **9**.
- 673 8. **Annous BA, Becker LA, Bayles DO, Labeda DP, Wilkinson BJ.** 1997. Critical role of
674 anteiso-C15:0 fatty acid in the growth of *Listeria monocytogenes* at low temperatures.
675 *Appl Environ Microbiol* **63**:3887-3894.
- 676 9. **Zhu K, Ding X, Julotok M, Wilkinson BJ.** 2005. Exogenous isoleucine and fatty acid
677 shortening ensure the high content of anteiso-C15:0 fatty acid required for low-
678 temperature growth of *Listeria monocytogenes*. *Appl Environ Microbiol* **71**:8002-8007.
- 679 10. **Giotis ES, McDowell DA, Blair IS, Wilkinson BJ.** 2007. Role of branched-chain fatty
680 acids in pH stress tolerance in *Listeria monocytogenes*. *Appl Environ Microbiol* **73**:997-
681 1001.
- 682 11. **Keeney K, Colosi L, Weber W, O'Riordan M.** 2009. Generation of branched-chain
683 fatty acids through lipoate-dependent metabolism facilitates intracellular growth of
684 *Listeria monocytogenes*. *J Bacteriol* **191**:2187-2196.
- 685 12. **Sun Y, O'Riordan MX.** 2010. Branched-chain fatty acids promote *Listeria*
686 *monocytogenes* intracellular infection and virulence. *Infect Immun* **78**:4667-4673.
- 687 13. **Sun Y, Wilkinson BJ, Standiford TJ, Akinbi HT, O'Riordan MX.** 2012. Fatty acids
688 regulate stress resistance and virulence factor production for *Listeria monocytogenes*. *J*
689 *Bacteriol* **194**:5274-5284.
- 690 14. **Rogiers G, Kebede BT, Van Loey A, Michiels CW.** 2017. Membrane fatty acid
691 composition as a determinant of *Listeria monocytogenes* sensitivity to trans-
692 cinnamaldehyde. *Res Microbiol* **168**:536-546.
- 693 15. **Chihib NE, Ribeiro da Silva M, Delattre G, Laroche M, Federighi M.** 2003. Different
694 cellular fatty acid pattern behaviours of two strains of *Listeria monocytogenes* Scott A
695 and CNL 895807 under different temperature and salinity conditions. *FEMS Microbiol*
696 *Lett* **218**:155-160.
- 697 16. **Zhu K, Bayles DO, Xiong A, Jayaswal RK, Wilkinson BJ.** 2005. Precursor and
698 temperature modulation of fatty acid composition and growth of *Listeria monocytogenes*
699 cold-sensitive mutants with transposon-interrupted branched-chain alpha-keto acid
700 dehydrogenase. *Microbiology* **151**:615-623.
- 701 17. **Singh AK, Zhang YM, Zhu K, Subramanian C, Li Z, Jayaswal RK, Gatto C, Rock**
702 **CO, Wilkinson BJ.** 2009. FabH selectivity for anteiso branched-chain fatty acid

- 703 precursors in low-temperature adaptation in *Listeria monocytogenes*. *FEMS Microbiol*
704 *Lett* **301**:188-192.
- 705 18. **Kaneda T.** 1991. Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and
706 taxonomic significance. *Microbiol Rev* **55**:288-302.
- 707 19. **Zhang YM, Rock CO.** 2008. Membrane lipid homeostasis in bacteria. *Nat Rev*
708 *Microbiol* **6**:222-233.
- 709 20. **Eisenreich W, Slaghuis J, Laupitz R, Bussemer J, Stritzker J, Schwarz C, Schwarz**
710 **R, Dandekar T, Goebel W, Bacher A.** 2006. ¹³C isotopologue perturbation studies of
711 *Listeria monocytogenes* carbon metabolism and its modulation by the virulence regulator
712 PrfA. *Proc Natl Acad Sci U S A* **103**:2040-2045.
- 713 21. **Brenner M, Lobel L, Borovok I, Sigal N, Herskovits AA.** 2018. Controlled branched-
714 chain amino acids auxotrophy in *Listeria monocytogenes* allows isoleucine to serve as a
715 host signal and virulence effector. *PLoS Genet* **14**:e1007283.
- 716 22. **Joseph B, Goebel W.** 2007. Life of *Listeria monocytogenes* in the host cells' cytosol.
717 *Microbes Infect* **9**:1188-1195.
- 718 23. **Brown SA, Palmer KL, Whiteley M.** 2008. Revisiting the host as a growth medium.
719 *Nat Rev Microbiol* **6**:657-666.
- 720 24. **Feyaerts J, Rogiers G, Corthouts J, Michiels CW.** 2015. Thiol-reactive natural
721 antimicrobials and high pressure treatment synergistically enhance bacterial inactivation.
722 *Innovative Food Science & Emerging Technologies* **27**:26-34.
- 723 25. **Bennett HJ, Pearce DM, Glenn S, Taylor CM, Kuhn M, Sonenshein AL, Andrew**
724 **PW, Roberts IS.** 2007. Characterization of *relA* and *codY* mutants of *Listeria*
725 *monocytogenes*: identification of the *CodY* regulon and its role in virulence. *Mol*
726 *Microbiol* **63**:1453-1467.
- 727 26. **Lobel L, Sigal N, Borovok I, Ruppin E, Herskovits AA.** 2012. Integrative genomic
728 analysis identifies isoleucine and *CodY* as regulators of *Listeria monocytogenes*
729 virulence. *PLoS Genet* **8**:e1002887.
- 730 27. **Lobel L, Sigal N, Borovok I, Belitsky BR, Sonenshein AL, Herskovits AA.** 2015. The
731 metabolic regulator *CodY* links *Listeria monocytogenes* metabolism to virulence by
732 directly activating the virulence regulatory gene *prfA*. *Mol Microbiol* **95**:624-644.
- 733 28. **Lobel L, Herskovits AA.** 2016. Systems Level Analyses Reveal Multiple Regulatory
734 Activities of *CodY* Controlling Metabolism, Motility and Virulence in *Listeria*
735 *monocytogenes*. *PLoS Genet* **12**:e1005870.
- 736 29. **Belitsky BR.** 2014. Role of *PdxR* in the activation of vitamin B6 biosynthesis in *Listeria*
737 *monocytogenes*. *Mol Microbiol* **92**:1113-1128.
- 738 30. **Biswas R, Sonenshein AL, Belitsky BR.** 2020. Genome-wide Identification of *Listeria*
739 *monocytogenes* *CodY*-Binding Sites. *Mol Microbiol* doi:10.1111/mmi.14449.
- 740 31. **Brinsmade SR.** 2017. *CodY*, a master integrator of metabolism and virulence in Gram-
741 positive bacteria. *Curr Genet* **63**:417-425.
- 742 32. **Sonenshein AL.** 2005. *CodY*, a global regulator of stationary phase and virulence in
743 Gram-positive bacteria. *Curr Opin Microbiol* **8**:203-207.
- 744 33. **Levdikov VM, Blagova E, Colledge VL, Lebedev AA, Williamson DC, Sonenshein**
745 **AL, Wilkinson AJ.** 2009. Structural rearrangement accompanying ligand binding in the
746 GAF domain of *CodY* from *Bacillus subtilis*. *J Mol Biol* **390**:1007-1018.

- 747 34. **Levdikov VM, Blagova E, Young VL, Belitsky BR, Lebedev A, Sonenshein AL,**
748 **Wilkinson AJ.** 2017. Structure of the Branched-chain Amino Acid and GTP-sensing
749 Global Regulator, CodY, from *Bacillus subtilis*. *J Biol Chem* **292**:2714-2728.
- 750 35. **Sen S, Sirobhushanam S, Hantak MP, Lawrence P, Brenna JT, Gatto C, Wilkinson**
751 **BJ.** 2015. Short branched-chain C6 carboxylic acids result in increased growth, novel
752 'unnatural' fatty acids and increased membrane fluidity in a *Listeria monocytogenes*
753 branched-chain fatty acid-deficient mutant. *Biochim Biophys Acta* **1851**:1406-1415.
- 754 36. **Auerbuch V, Lenz LL, Portnoy DA.** 2001. Development of a competitive index assay
755 to evaluate the virulence of *Listeria monocytogenes* actA mutants during primary and
756 secondary infection of mice. *Infect Immun* **69**:5953-5957.
- 757 37. **White SJ, McClung DM, Wilson JG, Roberts BN, Donaldson JR.** 2015. Influence of
758 pH on bile sensitivity amongst various strains of *Listeria monocytogenes* under aerobic
759 and anaerobic conditions. *J Med Microbiol* **64**:1287-1296.
- 760 38. **Begley M, Gahan CG, Hill C.** 2005. The interaction between bacteria and bile. *FEMS*
761 *Microbiol Rev* **29**:625-651.
- 762 39. **Santiago B, MacGilvray M, Faustoferri RC, Quivey RG, Jr.** 2012. The branched-
763 chain amino acid aminotransferase encoded by *ilvE* is involved in acid tolerance in
764 *Streptococcus mutans*. *J Bacteriol* **194**:2010-2019.
- 765 40. **Moat AG.** 2002. *Microbial Physiology*, 4th ed. Wiley-Liss.
- 766 41. **Smith K, Youngman P.** 1992. Use of a new integrational vector to investigate
767 compartment-specific expression of the *Bacillus subtilis* *spoIIM* gene. *Biochimie* **74**:705-
768 711.
- 769 42. **Lauer P, Chow MY, Loessner MJ, Portnoy DA, Calendar R.** 2002. Construction,
770 characterization, and use of two *Listeria monocytogenes* site-specific phage integration
771 vectors. *J Bacteriol* **184**:4177-4186.
- 772 43. **LeDeaux JR, Grossman AD.** 1995. Isolation and characterization of *kinC*, a gene that
773 encodes a sensor kinase homologous to the sporulation sensor kinases KinA and KinB in
774 *Bacillus subtilis*. *J Bacteriol* **177**:166-175.
- 775 44. **Arnaud M, Chastanet A, Debarbouille M.** 2004. New vector for efficient allelic
776 replacement in naturally nontransformable, low-GC-content, gram-positive bacteria. *Appl*
777 *Environ Microbiol* **70**:6887-6891.
- 778 45. **Livak KJ, Schmittgen TD.** 2001. Analysis of relative gene expression data using real-
779 time quantitative PCR and the $2^{-(\Delta\Delta C(T))}$ Method. *Methods* **25**:402-408.
- 780




Figure 1 Legend

Figure 1. Changes in Fatty Acid and BCAA content in *Lm* lacking *IlvE* or *CodY*. (A) Simplified overview of branched chain fatty acid (BCFA) biosynthesis in Gram-positive bacteria (based on detailed diagram in (9)) showing pathways that incorporate branched chain amino acids (BCAAs: Ile, Leu & Val). Red X represents points in pathways where deletion mutants were used in this study. Colored arrows indicate pathways of individual BCAAs that are incorporated into final BCFA isoforms (18). Purple text = enzyme names. (B and C) Graphs represent the relative amounts of the major fatty acids as a percentage of total fatty acids contained in *Lm* cultures of WT, $\Delta ilvE$, $\Delta ilvE::ilvE^+$ and $\Delta codY$ strains grown in nutrient limiting medium (LDM) to (B) mid-logarithmic and (C) stationary phase. Graphs represent combined data from three independent experiments. Graphs shown here and data in Tables 2 and 3 are the combined quantities of odd numbered (C15 and C17) or even-numbered (C14 and C16) BCFAs. Individual numbered species (e.g., ai-C15 only) and all other fatty acids are in Supplemental Tables S3 and S4. (D and E). Cultures of WT, $\Delta ilvE$, $\Delta ilvE::ilvE$ and $\Delta codY$ strains grown in LDM to (D) mid-logarithmic and (E) stationary phase were analyzed by mass spectrometry. Concentrations of BCAAs were normalized to total protein content and are shown as ratios relative to WT. Error bars show the range of fold difference compiled from 2 independent experiments.

Figure 2




Figure 2. Growth of $\Delta ilvE$ and $\Delta codY$ mutants in rich and nutrient-limited medium. Bacterial growth of WT (circles), $\Delta ilvE$ (triangles), $\Delta ilvE::ilvE^+$ (inverted triangles), and $\Delta codY$ (squares), was analyzed on a Bioscreen instrument. Samples were inoculated from recovered frozen cultures that had been prepared in LDM to mid-logarithmic phase. Optical Density at 600 nm (OD600) was measured for 24 hours at 37°C with shaking. Experiments include growth in (A) Rich medium = Brain Heart Infusion (BHI) and (B) LDM containing amino acids at 100 $\mu\text{g}/\text{mL}$. Data are compiled from three independent experiments with three technical replicates per experiment. Each point is the mean with error bars representing the Standard Deviation. (C) RT-qPCR analysis of *ilvE* expression in Lm grown in LDM to logarithmic (left) and stationary (right) phase.

Figure 2




Figure 3. Growth of *Lm* in LDM with variable exogenous BCAAs. Bacterial growth of WT (circles), $\Delta ilvE$ (triangles), $\Delta ilvE::ilvE^+$ (inverted triangles), and $\Delta codY$ (squares), performed as in Figure 2, but in LDM containing (A) no BCAAs, (B) no Ile (Val & Leu only), (C) no Leu (Ile & Val only), and (D) no Val (Ile & Leu only). Data are compiled from three independent experiments with three technical replicates per experiment. Each point is the mean with error bars representing standard deviation.

Figure 4




Figure 4. IlvE is required for optimal growth in macrophages and for cell-to-cell spread in cell culture. (A) Total CFU from survival assays of Lm infection of Bone Marrow Derived Macrophages (BMDM) assessed at 0.5, 4 and 8h post-infection. Data are compiled from three independent experiments showing mean and standard deviation. MOI = 1. (B-C) Plaque assay of Lm grown in L9 fibroblasts. (B) Representative image of plaques formed by WT & $\Delta ilvE$ bacteria after 48h growth. (C) Average plaque diameters from experiments that included WT, $\Delta ilvE$ and $\Delta ilvE::ilvE^+$ (left) or WT and $\Delta codY$ (right). Numbers below graphs are the mean plaque diameter with standard deviation compiled from three independent experiments. Two-tailed *t*-test comparing mutants to WT, **** $P < 0.0001$; ns = not significant.






Figure 5 Legend

Figure 5. *IlvE* is required for resistance to membrane stress in response to bile salts and for survival in a mouse model of listeriosis. (A) Log-phase bacteria grown in LDM were added to PBS with 0, 1, 2 and 4 mg/mL Bile Salts (Cholic acid-Deoxycholic acid sodium salt mixture) and incubated at 37°C for 30 minutes. Input for all samples was $\sim 10^7$ CFU/mL. Data are compiled from three independent experiments. One-way ANOVA (non-parametric) with Dunn's multiple comparisons post-test comparing mutant strains to WT. ns = not significant; * $P < 0.05$; *** $P < 0.001$; **** $P < 0.0001$. (B and C) Female C56BL/6 mice were infected with a 1:1 mixture of erythromycin-sensitive test strains and erythromycin-resistant WT strain via intraperitoneal injection. After 48h infection, (B) spleens and (D) livers were harvested and assessed for viable CFU and competitive index (CI) was calculated as the ratio of Sensitive/Resistant CFU. Data represent two independent experiments with total $n=7$ mice for all strains except WT, which was $n=8$. LOD = limit of detection.